• 1
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 75967.
  • 2
    Filipe MI, Branfoot AC. Mucin histochemistry of the colon. Curr Top Pathol 1976; 63: 14378.
  • 3
    Bara J, Languille O, Gendron MC, Daher N, Martin E, Burtin P. Immunohistological study of precancerous mucus modification in human distal colonic polyps. Cancer Res 1983; 43: 388591.
  • 4
    Dawson PA, Filipe MI. An ultrastructural and histochemical study of the mucous membrane adjacent to and remote from carcinoma of the colon. Cancer 1976; 37: 238898.
  • 5
    Bara J, Burtin P. Mucus-associated gastrointestinal antigens in transitional mucosa adjacent to human colonic adenocarcinomas: their ‘fetal-type’ association. Eur J Cancer 1980; 16: 130310.
  • 6
    Bara J, Andre J, Gautier R, Burtin P. Abnormal pattern of mucus-associated M1 antigens in histologically normal mucosa adjacent to colonic adenocarcinomas. Cancer Res 1984; 44: 40405.
  • 7
    Caderni G, Giannini A, Lancioni L, Luceri C, Biggeri A, Dolara P. Characterisation of aberrant crypt foci in carcinogen-treated rats: association with intestinal carcinogenesis. Br J Cancer 1995; 71: 7639.
  • 8
    Bara J, Forgue-Lafitte ME, Maurin N, Flejou JF, Zimber A. Abnormal expression of gastric mucin in human and rat aberrant crypt foci during colon carcinogenesis. Tumour Biol 2003; 24: 10915.
  • 9
    Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37: 14751.
  • 10
    Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51: 15647.
  • 11
    Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 15970.
  • 12
    Molatore S, Ranzani GN. Genetics of colorectal polyps. Tech Coloproctol 2004; 8 ( Suppl 2): s240s242.
  • 13
    McLellan EA, Medline A, Bird RP. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res 1991; 51: 52704.
  • 14
    Pretlow TP, O'Riordan MA, Somich GA, Amini SB, Pretlow TG. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 1992; 13: 150912.
  • 15
    Ochiai M, Ushigome M, Fujiwara K, Ubagai T, Kawamori T, Sugimura T, Nagao M, Nakagama H. Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Am J Pathol 2003; 163: 160714.
  • 16
    Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J Cell Biochem Suppl 1992; 16G: 5562.
  • 17
    Shpitz B, Hay K, Medline A, Bruce WR, Bull SB, Gallinger S, Stern H. Natural history of aberrant crypt foci. A surgical approach. Dis Colon Rectum 1996; 39: 7637.
  • 18
    Narisawa T, Sato T, Hayakawa M, Sakuma A, Nakano H. Carcinoma of the colon and rectum of rats by rectal infusion of N-methyl-N′-nitro-N-nitrosoguanidine. Gann 1971; 62: 2314.
  • 19
    Reddy BS, Weisburger JH, Narisawa T, Wynder EL. Colon carcinogenesis in germ-free rats with 1,2-dimethylhydrazine and N-methyl-n′-nitro-N-nitrosoguanidine. Cancer Res 1974; 34: 236872.
  • 20
    Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, Vogelstein B, Lengauer C. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci USA 2001; 98: 57705.
  • 21
    Decaens C, Bara J, Rosa B, Daher N, Burtin P. Early oncofetal antigenic modifications during rat colonic carcinogenesis. Cancer Res 1983; 43: 35562.
  • 22
    Bara J, Gautier R, Daher N, Zaghouani H, Decaens C. Monoclonal antibodies against oncofetal mucin M1 antigens associated with precancerous colonic mucosae. Cancer Res 1986; 46: 39839.
  • 23
    Bara J, Gautier R, Mouradian P, Decaens C, Daher N. Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis. Int J Cancer 1991; 47: 30410.
  • 24
    Nollet S, Forgue-Lafitte ME, Kirkham P, Bara J. Mapping of two new epitopes on the apomucin encoded by MUC5AC gene: expression in normal GI tract and colon tumors. Int J Cancer 2002; 99: 33643.
  • 25
    Bara J, Chastre E, Mahiou J, Singh RL, Forgue-Lafitte ME, Hollande E, Godeau F. Gastric M1 mucin, an early oncofetal marker of colon carcinogenesis, is encoded by the MUC5AC gene. Int J Cancer 1998; 75: 76773.
  • 26
    Nollet S, Escande F, Buisine MP, Forgue-Lafitte ME, Kirkham P, Okada Y, Bara J. Mapping of SOMU1 and M1 epitopes on the apomucin encoded by the 5′ end of the MUC5AC gene. Hybrid Hybridomics 2004; 23: 939.
  • 27
    Bara J, Decaens C, Loridon-Rosa B, Oriol R. Immunohistological characterization of mucin epitopes by pre-treatment of gastro-intestinal sections with periodic acid. J Immunol Methods 1992; 149: 10513.
  • 28
    Decaens C, Gautier R, Bara J, Daher N, Le Pendu J, Burtin P. A new mucin-associated oncofetal antigen, a marker of early carcinogenesis in rat colon. Cancer Res 1988; 48: 15717.
  • 29
    Decaens C, Nardelli J, Bara J, Burtin P. Biochemical characterization of a rat oncofetal colonic antigen defined by a monoclonal antibody raised against gastric surface epithelium. Biochem J 1993; 293 (Part 2): 5316.
  • 30
    Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43: 121.
  • 31
    Tachino N, Hayashi R, Liew C, Bailey G, Dashwood R. Evidence for ras gene mutation in 2-amino-3-methylimidazo[4,5-f]quinoline-induced colonic aberrant crypts in the rat. Mol Carcinog 1995; 120: 18792.
  • 32
    Pretlow TP, Pretlow TG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta 2005; 1756: 8396.
  • 33
    Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22: 28794.
  • 34
    Zhang H, Nordenskjold B, Dufmats M, Soderkvist P, Sun XF. K-ras mutations in colorectal adenocarcinomas and neighbouring transitional mucosa. Eur J Cancer 1998; 34: 20537.
  • 35
    Hirose Y, Kuno T, Yamada Y, Sakata K, Katayama M, Yoshida K, Qiao Z, Hata K, Yoshimi N, Mori H. Azoxymethane-induced β-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003; 24: 10711.
  • 36
    Yamada Y, Oyama T, Hirose Y, Hara A, Sugie S, Yoshida K, Yoshimi N, Mori H. β-Catenin mutation is selected during malignant transformation in colon carcinogenesis. Carcinogenesis 2003; 24: 917.
  • 37
    Caderni G, Femia AP, Giannini A, Favuzza A, Luceri C, Salvadori M, Dolara P. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 2003; 63: 238892.
  • 38
    Magnuson BA, Carr I, Bird RP. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 1993; 53: 4499504.
  • 39
    Fujimitsu Y, Nakanishi H, Inada K, Yamachika T, Ichinose M, Fukami H, Tatematsu M. Development of aberrant crypt foci involves a fission mechanism as revealed by isolation of aberrant crypts. Jpn J Cancer Res 1996; 87: 1199203.
  • 40
    Araki K, Ogata T, Kobayashi M, Yatani R. A morphological study on the histogenesis of human colorectal hyperplastic polyps. Gastroenterology 1995; 109: 146874.
  • 41
    Wong WM, Mandir N, Goodlad RA, Wong BC, Garcia SB, Lam SK, Wright NA. Histogenesis of human colorectal adenomas and hyperplastic polyps: the role of cell proliferation and crypt fission. Gut 2002; 50: 2127.
  • 42
    van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 24150.
  • 43
    Niitsu Y, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Abe T, Kogawa T, Takahashi M, Matsunaga T et al. Chemoprevention of colorectal cancer. Cancer Chemother Pharmacol 2004; 54 ( Suppl 1): S40S43.
  • 44
    Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, Li SS, Lampe PD, Bronner MP, Potter JD. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005; 14: 6058.